DUSP1 and non-small cell lung carcinoma: Another study conducted in NSCLC cell lines (PC-9 and HCC827) demonstrated that the overexpression of DUSP1 is responsible for the resistance to the EGFR tyrosine kinase inhibitor osimertinib by inhibiting ERK1/2 phosphorylation.